Abstract:In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is 'fully human', T cell epitopes that are contained in the sequences of the biologic may activate the immune system, enabling the development of anti-drug antibodies that can reduce drug efficacy and may contribute to adverse events. Computational tools that identify T cell epitopes from primary amino acid sequences have been used to assess the immunogenic potential of therapeutic candidates for several decades. To facilitate larger scale analyses and accelerate preclinical immunogenicity risk assessment, our group developed an integrated web-based platform called ISPRI, (Immunogenicity Screening and Protein Re-engineering Interface) that provides hands-on access through a secure web-based interface for scientists working in large and mid-sized biotech companies in the US, Europe, and Japan. This toolkit has evolved and now contains an array of algorithms that can be used individually and/or consecutively for immunogenicity assessment and protein engineering. Most analyses start with the advanced epitope mapping tool (EpiMatrix), then proceed to identify epitope clusters using ClustiMer, and then use a tool called JanusMatrix to define whether any of the T cell epitope clusters may generate a regulatory T cell response which may diminish or eliminate anti-drug antibody formation. Candidates can be compared to similar products on a normalized immunogenicity scale. Should modifications to the biologic sequence be an option, a tool for moderating putative immunogenicity by editing T cell epitopes out of the sequence is available (OptiMatrix). Although this perspective discusses the in-silico immunogenicity risk assessment for monoclonal antibodies, bi-specifics, multi-specifics, and antibody-drug conjugates, the analysis of additional therapeutic modalities such as enzyme replacement proteins, blood factor proteins, CAR-T, gene therapy products, and peptide drugs is also made available on the ISPRI platform. ISPRI (Interactive Screening and Protein Reengineering Interface) : Integrated, cloud-based, comprehensive toolkit for Immunogenicity Risk Assessment. EpiMatrix Immunogenicity Score : Combined T effector and Treg Epitope Content per unit protein. Tregitopes : Treg Epitopes found in IgG Framework that have been shown to modulate antigen-specific effector T cell responses. ClustiMer : Tool for identifying epitope rich polypeptides from within a given protein sequence. JanusMatrix : Tool for Predicting Tolerance, Putative Treg Epitopes, and Anti-self-immune responses. OptiMatrix : Tool for modifying T cell epitope sequences to reduce (or enhance) MHC binding.

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs

From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies

Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

Immunogenicity assessment strategy for a chemically modified therapeutic protein in clinical development

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins

Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection

Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies

Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Immune‐related adverse events of antibody‐based biological medicines in cancer therapy

Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies